Back to top
more

ICU Medical (ICUI)

(Delayed Data from NSDQ)

$94.84 USD

94.84
81,315

+0.31 (0.33%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $94.89 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merit Medical (MMSI) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Higher revenues, solid segmental performance and strong adjusted gross margins benefit Merit Medical's (MMSI) Q1 earnings. However, higher expenses remain a concern.

Stryker (SYK) Q1 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q1 earnings.

Quest Diagnostics (DGX) Q1 Earnings Top Mark, Margins Down

by Zacks Equity Research

Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.

Looking for a Growth Stock? 3 Reasons Why ICU Medical (ICUI) is a Solid Choice

by Zacks Equity Research

ICU Medical (ICUI) could produce exceptional returns because of its solid growth attributes.

Baxter (BAX) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Looking for a Growth Stock? 3 Reasons Why ICU Medical (ICUI) is a Solid Choice

by Zacks Equity Research

ICU Medical (ICUI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell (OMCL) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

What's in Store for AmerisourceBergen (ABC) in Q4 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.

What's in Store for Quidel (QDEL) This Earnings Season?

by Zacks Equity Research

Strong growth in Cardiac Immunoassay segment's revenues is likely to drive Quidel's (QDEL) top line in Q3.

Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?

by Zacks Equity Research

Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.

ICU Medical (ICUI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ICU Medical (ICUI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Match Group (MTCH) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Match Group (MTCH) boasts of a robust product portfolio comprising Tinder, Match.com, Meetic, PlentyOfFish and OkCupid.

Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) focus on R&D and strategic buyouts to drive Q2 results.

Why the Earnings Surprise Streak Could Continue for ICU Medical (ICUI)

by Zacks Equity Research

ICU Medical (ICUI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Orthofix (OFIX) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Orthofix (OFIX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

TG Therapeutics (TGTX) in Focus: Stock Moves 8.6% Higher

by Zacks Equity Research

TG Therapeutics (TGTX) shares rose nearly 9% in the last trading session, amid huge volumes.

    ICU Medical (ICUI) Enters Oversold Territory

    by Zacks Equity Research

    ICU Medical, Inc. (ICUI) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

      Sreyoshi Mukherjee headshot

      3 Top Stocks From the Booming US Medical Products Industry

      by Sreyoshi Mukherjee

      The U.S. Medical Products industry is sturdy on solid focus on technological advancement.

        Medical - Products Stock Outlook: Short-Term Pain Inevitable

        by Zacks Equity Research

        Near-term growth prospects of medical products are being questioned due to trade war apprehensions and President Trump's imposition of fresh tariffs on about $200 billion on Chinese imports.

          Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod

          by Zacks Equity Research

          The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.

            Why ICU Medical (ICUI) Might be Well Poised for a Surge

            by Zacks Equity Research

            ICU Medical (ICUI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

              Zacks.com featured highlights include: ICU Medical, FTI, Aspen, Old Dominion and Illumina

              by Zacks Equity Research

              Zacks.com featured highlights include: ICU Medical, FTI, Aspen, Old Dominion and Illumina

                5 Momentum Stocks Worth Investing in via Driehaus Strategy

                by Zacks Equity Research

                Using the "buy high and sell higher" rule, Richard Herman Driehaus has created an investment approach.

                  ICU Medical (ICUI) Tops Q2 Earnings and Revenue Estimates

                  by Zacks Equity Research

                  ICU Medical (ICUI) delivered earnings and revenue surprises of 45.36% and 7.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?